Physician profile
Thomas M Snyder
NPI 1750378311
$182,093.36
in general payments reported to CMS, 2019-2025
44 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $54K · 2021: $30K · 2022: $29K · 2023: $594 · 2024: $752 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $64,284.96 | 2019-2025 | Skyclarys, Skyclarys |
| Genentech USA, INC. | $29,959.68 | 2019-2024 | Ocrevus Zunovo, Ocrevus |
| Emd Serono, INC. | $23,463.75 | 2019-2025 | Mavenclad |
| Celgene Corporation | $20,847.35 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $15,945.60 | 2020-2024 | Zeposia |
| Genzyme Corporation | $13,929.06 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $8,263.76 | 2019-2023 | Ajovy |
| Janssen Pharmaceuticals, INC | $1,275.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $775.71 | 2019-2022 | |
| Amgen INC. | $428.27 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $412.63 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $366.67 | 2021-2023 | Uplizna |
| Allergan, INC. | $224.39 | 2019-2020 | |
| Lilly USA, LLC | $146.92 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Lundbeck LLC | $143.10 | 2019-2024 | Vyepti, Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.